Use of Inhibitors of the Renin-Angiotensin System

Abstract

It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.

1 . A method for the treatment of a person, wherein said method comprises administering to a person with hypertension and left ventricular hypertrophy in need of such treatment an inhibitor of the renin-angiotensin system wherein the inhibitor is an AT I  receptor antagonist comprises losartan in an amount effective to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. 
     
     
         2 . A method for the treatment of a person, wherein said method comprises administering to a person 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), an inhibitor of the renin-angiotensin system, wherein the inhibitor is an AT I  receptor antagonist comprises ramipril in an amount effective to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. 
     
     
         3 . The method of  claim 2 , wherein said method comprises administration of ramipril in addition to other needed treatment for said risk of developing a major cardiovascular event. 
     
     
         4 . The method of  claim 3 , wherein said other needed treatment is selected from the group consisting of: antihypertensive medication, anti-platelet aggregating factor medication, and lipid-lowering therapy. 
     
     
         5 . A method for the treatment of a person, wherein said method comprises administering to an adult patient with hypertension and type  2  diabetes mellitus in need of such treatment an inhibitor of the renin-angiotensin system, wherein the inhibitor is an AT I  receptor antagonist, wherein said inhibitor comprises irbesartan in an amount effective for the treatment of renal disease in said adult patient with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen. 
     
     
         6 . A method for the treatment of a person, wherein said method comprises administering to a patient with type 2 diabetes and hypertension in need of such treatment, an inhibitor of the renin-angiotensin system, wherein the inhibitor is an AT I  receptor antagonist, wherein said inhibitor comprises irbesartan in an amount effective for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in said patient with type 2 diabetes and hypertension, in an amount sufficient to reduce the progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation). 
     
     
         7 . A method for the treatment of a person with stable coronary artery disease with a history of myocardial infarction and/or revascularization, wherein said method comprises administering to a person with stable coronary artery disease in need of such treatment, an inhibitor of the renin-angiotensin system, wherein the inhibitor is an AT I  receptor antagonist, wherein said inhibitor comprises perindopril in an amount effective for the reduction of risk of cardiac events in said patient with a history of myocardial infarction and/or revascularization. 
     
     
         8 . A method for the treatment of a person with stable coronary artery disease, wherein said method comprises administering to a person with stable coronary artery disease in need of such treatment, an inhibitor of the renin-angiotensin system, wherein the inhibitor is an AT I  receptor antagonist, wherein said inhibitor comprises perindopril in an amount effective to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. 
     
     
         9 . The method of  claim 1 , wherein said method comprises administering to a person with hypertension and left ventricular hypertrophy in need of such treatment an inhibitor of the renin-angiotensin system wherein the inhibitor is an AT I  receptor antagonist and wherein said antagonist consists essentially of losartan in an amount effective to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. 
     
     
         10 . (canceled) 
     
     
         11 . The method of  claim 9 , said losartan provided as an oral finished pharmaceutical dosage form including at least one pharmaceutically acceptable excipient.